Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001248601 | SCV001422100 | uncertain significance | RYR1-related disorder | 2022-08-24 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 2017 of the RYR1 protein (p.Asp2017Gly). This variant is present in population databases (no rsID available, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with RYR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 972545). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RYR1 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Fulgent Genetics, |
RCV002480858 | SCV002788759 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-07-29 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV003365292 | SCV004064052 | uncertain significance | Inborn genetic diseases | 2023-09-14 | criteria provided, single submitter | clinical testing | The c.6050A>G (p.D2017G) alteration is located in exon 37 (coding exon 37) of the RYR1 gene. This alteration results from a A to G substitution at nucleotide position 6050, causing the aspartic acid (D) at amino acid position 2017 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Revvity Omics, |
RCV003490158 | SCV004236860 | uncertain significance | not provided | 2023-06-30 | criteria provided, single submitter | clinical testing | |
| All of Us Research Program, |
RCV004004916 | SCV004820868 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2024-09-24 | criteria provided, single submitter | clinical testing | This missense variant replaces aspartic acid with glycine at codon 2017 of the RYR1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RYR1-related disorders in the literature. This variant has been identified in 2/282864 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |